中危非肌层浸润性膀胱癌维持治疗的价值:基于IBCG风险分层的分析
该研究基于2010-2023年前瞻性数据库,纳入464例接受膀胱灌注化疗或BCG的中危非肌层浸润性膀胱癌患者,按IBCG预后算法分层。中位随访57个月,139例(30%)复发。无IBCG危险因素者维持治疗无显著获益,而1-2个或≥3个危险因素者接受诱导+维持治疗与更低复发风险相关。
要点
- IBCG算法可有效分层中危NMIBC的复发风险。
- 无IBCG危险因素者,维持治疗未显著降低复发风险。
- 有1-2个或≥3个IBCG危险因素者,维持治疗与更低复发风险相关。
核心结论
- 在中危非肌层浸润性膀胱癌患者中,IBCG算法可有效分层复发风险,维持治疗仅对具有1-2个或≥3个IBCG危险因素的患者与更低复发率相关,对无危险因素者无显著获益。
研究设计与样本
- 基于2010-2023年前瞻性维护数据库的观察性队列研究,纳入464例接受膀胱灌注化疗或BCG的中危NMIBC患者。
- 患者按IBCG预后算法分为无、1-2个和≥3个危险因素三组,所有患者接受至少6次诱导灌注。
- 采用3个月里程碑堆叠累积发病率及多因素Cox回归模型评估维持治疗对复发和进展风险的影响。
主要发现
- 464例中205例(44%)接受BCG治疗,259例(56%)接受膀胱灌注化疗;维持灌注次数中位数(IQR)为9(5-11)。
- 中位随访57个月,139例(30%)患者出现复发。
- 无IBCG危险因素者5年复发风险:仅诱导 vs 诱导+维持为7.7% vs 7.3%(HR 0.78,95%CI 0.49-1.37)。
- 1-2个IBCG危险因素者5年复发风险:16% vs 13%(HR 0.65,95%CI 0.48-0.82)。
- ≥3个IBCG危险因素者5年复发风险:21% vs 17%(HR 0.48,95%CI 0.25-0.85)。
关键数值与推荐
- IBCG预后算法将患者分为无、1-2个和≥3个危险因素三组。
- 维持治疗获益定义:仅诱导 vs 诱导+维持的复发风险比较。
- 无危险因素组HR 0.78(95%CI 0.49-1.37);1-2个危险因素组HR 0.65(95%CI 0.48-0.82);≥3个危险因素组HR 0.48(95%CI 0.25-0.85)。
临床怎么用
- 对于中危NMIBC患者,可采用IBCG算法进行风险分层以指导维持治疗决策。
- 无IBCG危险因素的患者可能无需常规维持治疗,而有1-2个或≥3个危险因素的患者可从维持治疗中获益。
局限性
- 本研究为观察性队列研究,存在选择偏倚等混杂因素可能。
- 维持治疗获益基于非随机比较,需谨慎解读因果关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate which subgroups of patients with intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) benefit from maintenance therapy based on the International Bladder Cancer Group (IBCG) risk stratification, as the role of a maintenance course in patients with IR-NMIBC is debated. PATIENTS AND METHODS: We relied on a prospectively maintained database of patients with IR-NMIBC who received intravesical chemotherapy or Bacillus Calmette-Guérin (BCG) (2010-2023). Patients were stratified according the IBCG prognostic algorithm (no, one to two, and three or more risk factors). All patients received at least six induction instillations after index transurethral resection of bladder tumour. We used 3-month landmark stacked cumulative incidence and multivariable Cox regression models to assess the benefit from a maintenance course in terms of risk of recurrence and progression according to the IBCG risk groups stratification. RESULTS: Among 464 patients, 205 (44%) received BCG treatment and 259 (56%) received intravesical chemotherapy. The median (interquartile range) number of maintenance instillations was 9 (5-11). Over a median follow-up of 57 months, 139 (30%) patients had a recurrence. Patients with no IBCG risk factors had a similar risk of 5-year disease recurrence according to treatment duration (7.7% vs 7.3%; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.49-1.37, for induction only vs induction plus maintenance, respectively), whereas patients with one to two (5-year risk: 16% vs 13%; HR 0.65, 95% CI 0.48-0.82) or three or more IBCG risk factors (5-year risk: 21% vs 17%; HR 0.48, 95% CI 0.25-0.85) were associated with lower hazards of recurrence if treated with an induction plus maintenance course. CONCLUSIONS: The IBCG algorithm effectively stratifies patients with IR-NMIBC by recurrence risk. In this observational cohort, maintenance therapy was associated with lower recurrence rates in patients with one to two or three or more IBCG risk factors, but not in those with no risk factors. These findings suggest that the IBCG stratification may inform risk-adapted treatment decisions in patients with IR-NMIBC.
引用
- Zaurito P, Scilipoti P, Longoni M, et al. The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 40844867. doi:10.1111/bju.16905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。